Abiomed touts new Impella study results

Abiomed’s Impella 2.5 pump (Image from Abiomed)

New data on Abiomed (NSDQ:ABMD) Impella heart pumps show a 34% increase in survival among nearly 5,000 patients treated with the company’s devices intended to treat cardiogenic shock when combined with best practices, according to a company study.

The study of patients treated at 763 U.S. sites between April 1, 2018 and March 28, 2019 showed median survival rates had risen from 51% in 2016, when the FDA granted premarket approval for the Impella 2.5, CP, 5.0 and LD heart pumps, to 67%, the Danvers, Mass.-based company said. (The FDA approved Impella 2.5 for high-risk cardiogenic shock patients in March 2015.)

Get the full story on our sister site, Medical Design & Outsourcing.

The post Abiomed touts new Impella study results appeared first on MassDevice.

from MassDevice http://bit.ly/2Ih7gpc